Brief: Cantargia Presents New Data At SITC 2022 Supporting Nadunolimab's Promising Antitumor Clinical Efficacy

Cantargia AB

07/11/2022 15:13

Nov 7 (Reuters) - Cantargia AB  CANTA.ST :
    * CANTARGIA PRESENTS NEW DATA AT SITC 2022 SUPPORTING
NADUNOLIMAB'S PROMISING ANTITUMOR CLINICAL EFFICACY
    * PDAC AND NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
TREATED
WITH NADUNOLIMAB AND CHEMOTHERAPY SHOWED REDUCTIONS IN SAME
MOLECULES

Source text for Eikon:  ID:nWkrb6jZ3f 
Further company coverage:  CANTA.ST 
 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))